Table 1

Selected results from four mortality studies of the Dow dioxin cohort

Authors and year of publication
Cook et al, 19867Cook et al, 19878; 
 Ott et al, 19879Bond et al, 19896Current study
Years of follow up1940–791940–821940–841940–94
Number of workers2189218721922187
% deceased14171930
Cause of death 
  (ICDA-8 rubric)SMR (95% CI) [obs/exp]SMR (95% CI) [obs/exp]SMR (95% CI) [obs/exp]SMR (95% CI) [obs/exp]
All causes (001–999)0.9 (0.8 to 1.0) [298/327.5]0.9 (0.8 to 1.0) [370/396.0]0.9 (0.8 to 1.0) [406/441.3]0.9 (0.8 to 1.0) [655/721.1]
All cancer (140–209)1.0 (0.7 to 1.2) [61/63.5]1.0 (0.8 to 1.3) [81/79.3]1.0 (0.8 to 1.3) [95/92.2]1.0 (0.8 to 1.1) [168/170.4]
Lung cancer (162)0.8 (0.5 to 1.3) [18/22.0]0.8 (0.5 to 1.2) [23/27.9]0.9 (0.6 to 1.2) [28/33.0]0.8 (0.6 to 1.1) [54/62.5]
Soft tissue sarcoma (171)3.3 (0.1 to 18.6) [1/0.3]2.5 (0.1 to 13.9) [1/0.4]5.0 (0.6 to 18.1) [2/0.4]2.4 (0.3 to 8.6) [2/0.8]
Non-Hodgkin’s lymphoma 
  (200, 202)2.3 (0.8 to 5.6) [5/2.1]1.9 (0.6 to 4.5) [5/2.6]2.1 (0.8 to 4.5) [6/2.9]1.4 (0.6 to 2.7) [8/5.8]
All remaining cancers0.9 (0.7 to 1.3) [37/39.1]1.1 (0.8 to 1.4) [52/48.4]1.1 (0.8 to 1.4) [59/56.1]1.0 (0.8 to 1.2) [104/101.3]